Early empirical evidence provides grounds for optimism about eliminating HCV by 2030
Curative direct‐acting antiviral (DAA) therapy for people with chronic hepatitis C virus (HCV) infections1 has transformed clinical management and spurred ambitious World Health Organization elimination targets for 2030.2 WHO service targets encompass marked improvements in prevention, diagnosis, and treatment; impact targets include a 65% reduction in HCV‐related deaths and an 80% reduction in new HCV infections compared with 2015.2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 2019; 394: 1451–1466.
- 2. Word Health Organization. Global health sector strategy on viral hepatitis, 2016–2021 (WHO/HIV/2016.06). Geneva: WHO, 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (viewed Mar 2020).
- 3. Hajarizadeh B, Grebely J, Matthews GV, et al. Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat 2018; 25: 640–648.
- 4. Iversen J, Dore GJ, Catlett B, et al. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol 2019; 70: 33–39.
- 5. Iranpour N DG, Martinello M, Matthews G, et al. Estimated uptake of hepatitis C direct‐acting antiviral treatment among individuals with HIV co‐infection in Australia: a retrospective cohort study. Sexual Health 2020; https://doi.org/10.1071/sh19101 [Epub ahead of print].
- 6. Moon S, Erickson E. Universal medicine access through lump‐sum remuneration: Australia's approach to hepatitis C. N Engl J Med 2019; 380: 607–610.
- 7. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus‐related liver disease burden in the direct‐acting antiviral therapy era in New South Wales, Australia. J Hepatol 2019; 71: 281–288.
- 8. Scott N, Sacks‐Davis R, Wade AJ, et al. Australia needs to increase testing to achieve hepatitis C elimination. Med J Aust 2020; 212: 365–370.
- 9. NSW Government. NSW hepatitis B and hepatitis C strategies 2014–2020 data report: 2018 annual data report. 2018. https://www.health.nsw.gov.au/hepatitis/Publications/2018-annual-data-report.pdf (viewed Mar 2020).
- 10. Larney S, Peacock A, Leung J, et al. Global, regional, and country‐level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 2017; 5: e1208–e1220.
- 11. Fraser H, Zibbell J, Hoerger T, et al. Scaling‐up HCV prevention and treatment interventions in rural United States‐ model projections for tackling an increasing epidemic. Addiction 2017; 113: 173–182.
- 12. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (issue 10). June 2019. https://kirby.unsw.edu.au/report/monitoring-hepatitis-c-treatment-uptake-australia-issue-10-june-2019 (viewed Mar 2020).
Gregory Dore is an advisory board member and has received honoraria, research grant funding, and travel sponsorship from Merck, Gilead, and Abbvie.